肿瘤一站式综合诊疗服务

Search documents
海吉亚医疗:2025年中期净利润2.47亿元 同比下降35.76%
Sou Hu Cai Jing· 2025-09-25 11:30
Company Overview - The company primarily engages in medical services, operating two segments: hospital services and other business segments, focusing on comprehensive cancer diagnosis and treatment services [10] Financial Performance - The company's revenue and net profit growth rates have shown fluctuations over the years, with a notable increase in revenue in 2021 and a decline in 2022 [12] - For the first half of 2025, the company reported a revenue of 23.81 billion, with a year-on-year growth rate of 9.06% [12] - The average return on equity for the first half of 2025 was 3.68%, a decrease of 2.28 percentage points compared to the same period last year [20] Revenue Composition - In the first half of 2025, the revenue composition included significant contributions from inpatient services and outpatient services [13] Asset and Liability Changes - As of the first half of 2025, the company's cash and cash equivalents increased by 70.63%, while trading financial assets decreased by 76.8% [26] - Long-term borrowings decreased by 10.26%, while short-term borrowings increased by 16.63% [29] Financial Ratios - The company's current ratio was 0.96, and the quick ratio was 0.86 as of the first half of 2025 [33] - The asset-liability ratio has shown a decreasing trend, with the latest figure at 33.04% [31]